Edgar Filing: NOVARTIS AG - Form 4

NOVARTIS Form 4 August 16, 24 FORM Check thi if no long subject to Section 14 Form 4 ou Form 5 obligation may conti <i>See</i> Instru 1(b).	018 J 4 UNITED S s box s box s box STATEM 6. r Filed purs Section 17(a)	IENT OF suant to Se a) of the P	Was CHAN ection 16 ublic Ut	hington, GES IN I SECUR	D.C. 209 BENEFI ITIES e Securiti ling Com	549 CIA ies E	L OW xchang	COMMISSION NERSHIP OF e Act of 1934, f 1935 or Sectio 40	OMB Number: Expires: Estimated a burden hou response	irs per	
1. Name and A Novartis Bic	2. Issuer Name and Ticker or Trading Symbol AILERON THERAPEUTICS INC [ALRN]					5. Relationship of Reporting Person(s) to Issuer (Check all applicable)					
(3. Date of Earliest Transaction (Month/Day/Year) 08/14/2018					DirectorX 10% Owner Officer (give title Other (specify below)			
(Street) 4. If Amendment, Date Original 6. Individu Filed(Month/Day/Year) Applicable					Applicable Line)	Joint/Group Filing(Check One Reporting Person y More than One Reporting					
BASEL, V8 CH-4002 Person											
(City) 1.Title of Security (Instr. 3)	(State) 2. Transaction Date (Month/Day/Year)		ed Date, if	3. Transactic Code (Instr. 8) Code V	4. Securi on(A) or Di (D) (Instr. 3,	ties A	cquired d of	Juired, Disposed of 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	f, or Beneficial 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	-	
Common Stock	08/14/2018			S	3,300	D	\$ 2.26 (1)	2,437,413	D (2)		
Common Stock	08/15/2018			S	2,635	D	\$ 2.15 (3)	2,434,778	D <u>(2)</u>		

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of
information contained in this form are not
required to respond unless the formSEC 1474
(9-02)

Edgar Filing: NOVARTIS AG - Form 4

displays a currently valid OMB control number.

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	4. Transactic Code (Instr. 8)	5. ofNumber of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)			7. Titl Amou Under Secur (Instr.	ınt of rlying	8. Price of Derivative Security (Instr. 5)	9. Nu Deriv Secu Bene Owna Follo Repo Trans (Instr
			Code V	(A) (D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares		

Reporting Owners

Reporting Owner Name / Address	Relationships					
	Director	10% Owner	Officer	Other		
Novartis Bioventures Ltd C/O NOVARTIS INTERNATIONAL AG WSJ-200.220 BASEL, V8 CH-4002		Х				
NOVARTIS AG LICHTSTRASSE 35 BASEL, V8 CH 4056		Х				

Signatures

/s/ Bartosz Dzikowski, Secretary of the Board of Novartis Bioventures Ltd					
**Signature of Reporting Person	Date				
/s/ Florian Muellershausen, Authorized Signatory on behalf of Novartis					
Bioventures Ltd	08/16/2018				
**Signature of Reporting Person	Date				
/s/ Bartosz Dzikowski, Authorized Signatory on behalf of Novartis AG	08/16/2018				
**Signature of Reporting Person	Date				
/s/ Florian Muellershausen, Authorized Signatory on behalf of Novartis AG	08/16/2018				
<u>**</u> Signature of Reporting Person	Date				

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Reflects sales of common stock executed in multiple transactions at prices ranging from \$2.17 to \$2.33. The price reported reflects the weighted average sale price. The Reporting Persons hereby undertake to provide upon request to the Securities and Exchange

(1) Weighted average sale price. The Reporting reasons hereby undertake to provide upon request to the securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected.

(2) The shares are directly owned by Novartis Bioventures Ltd. Novartis Bioventures Ltd is a wholly-owned indirect subsidiary of Novartis AG, which is an indirect beneficial owner of the reported securities.

Reflects sales of common stock executed in multiple transactions at prices ranging from \$2.13 to \$2.25. The price reported reflects the weighted average sale price. The Reporting Persons hereby undertake to provide upon request to the Securities and Exchange

(3) Weighted average successful reporting reasons hereby undertake to provide upon request to the becames and Exchange
 (3) Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.